A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
This is a phase I/II, multi-center, open-label study of YH003 in combination with Toripalimab
(anti-PD-1 mAb). The study is comprised of a dose escalation part (Part I) exploring
escalating doses of YH003 in combination with fixed dose toripalimab in subjects with
advanced solid tumors (Part I), followed by an expansion part (Part II) with three expansion
cohorts.